Open tender · Germany · Contract notice
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betahistin, ATC N07CA01 für die Zeit 01.02.26 - 31.01.28 (zzgl. Verlängerungsoption 1x12 Monate)
DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betahistin, ATC N07CA01 für die Zeit 01.02.26 - 31.01.28…”. Bids close on 5 December 2028.
The work
Non-exclusive discount agreement for the active substance Betahistin, ATC N07CA01, for the period 01.02.26 - 31.01.28 with a 1x12 month extension option.
- Agreement ends automatically with the entry into force of an exclusive contract for the same substance.
Key facts
- Contract period
- 01.02.2026 - 31.01.2028 (plus 1x12 month extension option)
- Evaluation
- Selection criteria are in the application letter.
What it takes to qualify
Worth a closer look
- § 130a Abs. 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicinal products to be charged to the statutory health insurance funds.
- The procedure is not considered to be in the scope of cartel procurement law due to the lack of a selection decision and the resulting non-discriminatory access for all pharmaceutical companies.
- The tender is published using the form for open procedures, although it is not one, due to technical reasons as no suitable form for approval procedures exists.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- Angebotsschreibensubmitted via email
- Anerkennung der vertraglichen Maßgaben der DAK-Gesundheitsigned contract with name or company stamp
- Anlage 1 zum Vertragfilled out and submitted via email
- Anlage 2 zum VertragExcel file submitted via email